Cyclophosphamide — Drug Intelligence | 183 EU Trials

Filter these 183 trials by condition, phase, country and more.

Open in Search →

183 Registered trials

92 Recruiting

72 Completed trials

98 Sponsors

23 Countries

Phase III

Phase II

Phase III: 63 Phase II/III: 8 Phase II: 75 Phase I/II: 17 Phase IV: 6 Phase I: 2 Phase I (Other): 3 Phase I (FiH): 9

Oversight events:

6 serious breaches 58 temporary halts 4 urgent safety measures 6 unexpected events 8 corrective measures across 25 trials

View oversight register →

Indications tested

Diffuse large B-cell lymphoma 12 Triple negative breast cancer 5 Neuroblastoma 5 Ewing's sarcoma 5 Systemic lupus erythematosus 4 Follicular lymphoma 4 Lupus nephritis 3 B-cell lymphoma refractory 3 Breast cancer 3 Ependymoma 2 Medulloblastoma 2 Rhabdomyosarcoma 2

Sponsors using this IMP

Novartis Pharma AG 11 Ospedale Pediatrico Bambino Gesu 6 The University Of Birmingham 6 Fondazione Gimema Franco Mandelli Onlus 5 Iovance Biotherapeutics Inc. 5 LYSARC 5 Merck Sharp & Dohme LLC 5 Assistance Publique Hopitaux De Paris 4 AstraZeneca AB 4 Celgene Corp. 4 Centre Hospitalier Universitaire De Nantes 4 GPOH gGmbH 4

All trials

183 total

DALY II USA/MB-CART2019.1 for DLBCL Pending

2023-508508-39-01 Phase II 2 countries Miltenyi Biomedicine GmbH
IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending

2023-509392-17-00 Phase III 11 countries Charite Universitaetsmedizin Berlin KöR
A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral… Pending

2024-511567-28-01 Phase II 1 country Kooperativni Lymfomova Skupina z.s.
A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R… Pending

2024-513445-37-00 Phase III 4 countries University Of Cologne
SIOP PNET 5 medulloblastoma Pending

2024-513724-42-00 Phase II/III 10 countries University Medical Center Hamburg-Eppendorf
Dose monitoring of commonly used cytostatic drugs for breast cancer Pending

2024-514818-12-00 Phase IV 1 country Karolinska Institutet
Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) Pending

2024-517133-40-00 Phase III 5 countries GPOH gGmbH
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients … Pending

2024-517295-37-00 Phase III 1 country University Of Cologne
Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very Hi… Pending

2024-518912-37-01 Phase II 1 country Fondazione Santobono Pausilipon Onlus
Chemoimmunotherapy in conjunction with blood-brain-barrier opening in patients with newly diagnosed or relapsed primary central nervous syst… Pending

2024-519046-79-00 Phase II 1 country Oulu University Hospital
Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending

2024-519655-28-00 Phase III 7 countries Unicancer
A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY TO DETERMINE THE SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN PARTICIPANTS WITH SEVE… Pending

2024-519941-32-00 Phase II 1 country Autolus Limited
Reduced post-transplant cyclophosphamide dose in patients undergoing haploidentical hematopoietic stem cell transplantation for hematologica… Pending

2024-519986-23-00 Phase III 1 country Assistance Publique Hopitaux De Paris
A phase 2, Multicenter Study of TILs Treatment in Germ Cell tumors: the ARES Study Pending

2025-522427-10-00 Phase II 1 country Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL
A clinical trial to learn more about the effects of DJI136 in people with extensive-stage small cell lung cancer Pending

2025-523276-23-00 Phase I (FiH) 2 countries Novartis Pharma AG
Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy Pending

2025-524278-40-00 Phase IV 1 country Universitair Ziekenhuis Gent
A study to test the safety and disease progression following YTB323 (rapcabtagene autoleucel) administration in participant with progressive… Recruiting

2024-514006-31-00 Phase I/II 4 countries Novartis Pharma AG
A Phase 1/2a Study of UCART20x22 in B-Cell Non-Hodgkin Lymphoma [NatHaLi-01] Recruiting

2022-501607-27-00 Phase I (FiH) 3 countries Cellectis
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. Recruiting

2025-522052-13-00 Phase II/III 9 countries Ospedale Pediatrico Bambino Gesu
Study to investigate lifileucel regimen plus pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melano… Recruiting

2022-503140-41-00 Phase III 12 countries Iovance Biotherapeutics Inc.
A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be… Recruiting

2024-510778-26-00 Phase II 6 countries Iovance Biotherapeutics Inc.
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Phase III 5 countries Unicancer
HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting

2025-521040-37-00 Phase III 4 countries Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques Augus…
An open-label study to assess the safety, efficacy, and cellular kinetics of YTB323 (rapcabtagene autoleucel) in Relapsingin Relapsing Multi… Recruiting

2024-512714-18-00 Phase I/II 4 countries Novartis Pharma AG

Showing 1–24 of 183 trials

← All drugs A–Z